期刊文献+

中医特色护理干预对化疗治疗NSCLC的毒副反应影响观察 被引量:2

Impact Observation of Traditional Chinese Medicine Special Nursing Intervention on Toxic and Side Effects for NSCLC Chemotherapy
下载PDF
导出
摘要 目的:观察中医特色护理干预对化疗治疗NSCLC的毒副反应影响。方法:选择我院2017年3月~2019年1月收治的94例患者,依据患者意愿半随机将94例患者匹配成53例观察组与41例对照组,分别予以常规护理^+中医特色护理干预和常规护理。记录两组护理期间出现的毒副反应;对比分析两组干预前后免疫功能变化及生活质量评分。结果:毒副反应发生率对比:观察组32.08%显著低于对照组51.60%(P<0.05);免疫功能对比:观察组干预后CD3^+、CD4^+、CD4^+/CD8^+均较对照组低,CD8^+较对照组高(P<0.05);生活质量评分对比:观察组干预后WHOQOL-100量表各维度评分皆高于对照组(P<0.05)。结论:中医特色护理干预可降低化疗治疗NSCLC的毒副反应,对患者免疫功能及生活质量均有一定改善作用,具有临床借鉴价值。 Objective:To observe the effect of traditional Chinese medicine(TCM)special nursing intervention on toxic and side effects for NSCLC chemotherapy.Methods:A total of 94 patients who were admitted to the hospital from March 2017 to January 2019 were enrolled.According to patients'willingness,they were semi-randomly divided into observation group(53 cases)and controlled group(41 cases).The two groups were given routine nursing combined with TCM special nursing intervention or routine nursing,respectively.The toxic and side effects during nursing period in both groups were recorded.The immune function changes and quality of life scores before and after intervention were compared between the two groups.Results:The incidence of toxic and side effects in the observation group was significantly lower than that in the controlled group(32.08%vs 51.60%)(P<0.05).Comparison of immune function:After intervention,CD3^+,CD4^+ and CD4^+/CD8^+ in the observation group were lower than those in the controlled group,while CD8^+ was higher than that in the controlled group(P<0.05).Comparison of quality of life scores:After intervention,scores of WHOQOL-100 scale in all dimensions in the observation group were higher than those in the controlled group(P<0.05).Conclusion:TCM special nursing intervention can reduce toxic and side effects of NSCLC chemotherapy,which can improve immune function and quality of life,and is of clinical reference value.
作者 程清 郭蕾 严思又 彭丽 黄美玲 沈琳 蔡伦华 CHENG Qing;GUO Lei;YAN Siyou(Department of Oncology,Sichuan Provincial Cancer Hospital,Chengdu Sichuan 610041,China;Career Development Department,Sichuan Provincial Cancer Hospital,Chengdu Sichuan 610041,China)
出处 《四川中医》 2020年第7期208-211,共4页 Journal of Sichuan of Traditional Chinese Medicine
关键词 中医特色护理 非小细胞 毒副反应 免疫功能 生活质量 Traditional Chinese medicine special nursing Non-small cell Toxic and side effect Immune function Quality of life
  • 相关文献

参考文献13

二级参考文献106

  • 1郑积华,张为民,谢波,林金容,周娟,徐志勇.多西他赛或培美曲塞一线治疗老年晚期肺腺癌的疗效及预后因素分析[J].肿瘤防治研究,2014,41(6):641-644. 被引量:8
  • 2王勇,江丰收,孙玉蓓,胡冰.肺癌患者血清VEGF的表达及其临床意义[J].临床肺科杂志,2007,12(8):804-804. 被引量:12
  • 3HENSCHKE CI, YANKELEVITZ DF, LIBBY DM, et al. Survival of patients with stage Ⅰ lung cancer detected on CT screening[J]. N Engl J Med, 2006, 355(17) :1763-1771. 被引量:1
  • 4LARSEN SS, VILMANN P, KRASNIK M, et al. Endoscopic ultrasound guided biopsy performed routinely in lung cancer staging spares futile thoracotomies: preliminary results from a randomized clinical trial[J]. Lung Cancer, 2005, 49(3) :377-385. 被引量:1
  • 5CRAANEN ME, COMANS EF, PAUL MA, et al. Endoscopic ultrasound guided fine-needle aspiration and 18FDG-positron emission tomography in the evaluation of patients with non-small cell lung cancer[ J ]. Interact Cardiovasc Thorac Surg, 2007, 6 ( 4 ) : 433-436. 被引量:1
  • 6VAN ZANDWIJK N, MATHY A, BOERRIGTER L, et al. EGFR and K-RAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small cell lung cancer[J]. Ann Oncol, 2007, 18(1) : 99-103. 被引量:1
  • 7ONISHI H, SHIRATO H, NAGATA Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study[ J ]. J Thorac Oncol, 2007, 2 ( 7 Suppl 3) :S94-100. 被引量:1
  • 8WISNIVESKY JP, BONOMI M, HENSCHKE C, et al. Radiation therapy for the treatment of unresected stage Ⅰ - Ⅱ non-small cell lung cancer [ J ]. Chest, 2005 , 128 (3) : 146! -1467. 被引量:1
  • 9STRAUSS G M, HERNDON J E, MADDAUS M A, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ⅰ b non-small cell lung cancer (NSCLC) : report of Cancer and Leukemia Group B (CALGB) Protocol 9633 [ R]. Proc ASCO, 2006,24 (18s) :365. 被引量:1
  • 10DOUILLARD J Y, ROSELL R, DE LENA M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage Ⅰ b-Ⅲ a non-small cell lung cancer (Adjuvant Navelbine International Trialist Association (ANITA) : a randomized controlled trial[ J ]. Lancet, 2006,7 (9) : 719-727. 被引量:1

共引文献244

同被引文献15

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部